Pharmacological inhibition of PDE7 using BRL-50481 enhances cAMP-PKA-dependent apoptosis in CLL cells, further supporting its therapeutic relevance (69). The gene discussed is PDE7A; the disease is B-cell chronic lymphocytic leukemia.